Literature DB >> 10458404

Clearance mechanism of prostate specific antigen and its complexes with alpha2-macroglobulin and alpha1-antichymotrypsin.

G Birkenmeier1, F Struck, R Gebhardt.   

Abstract

PURPOSE: To investigate the rate of elimination of prostate specific antigen (PSA) and its complexes with human alpha2-macroglobulin (alpha2-M) and alpha1-antichymotrypsin (ACT) and to elucidate the role of the alpha2-macroglobulin-receptor/low density lipoprotein receptor-related protein (alpha2-M-R/LRP) in the clearance mechanism.
MATERIALS AND METHODS: PSA and complexes of PSA with alpha2-M and ACT were prepared and radiolabeled with [125I]Na (Amersham, Braunschweig, Germany). Radiolabeled proteins were injected into rats and the elimination of radioactivity from circulation was measured by gamma-counting of 20 microL aliquots over time. After 30 minutes different organs were removed and the total radioactivity was counted. The elimination rate and distribution of PSA and PSA-complexes was studied in the absence and presence of an excess of transformed alpha2-M.
RESULTS: Radiolabeled PSA is rapidly eliminated from circulation with an initial half-life of 6.4+/-2.1 minutes mainly due to extraction by the liver and kidney. The clearance is slightly inhibited by transformed alpha2-M. PSA-alpha2-M is solely eliminated by the liver with a half-life of 6.7+/-1 minutes. Uptake by the liver is competitively inhibited by transformed alpha2-M. PSA-ACT is eliminated by the liver and kidney with an initial half-life of 3.51+/-1.1 minutes. Transformed alpha2-M failed to inhibit the clearance of PSA-ACT.
CONCLUSIONS: Free PSA and PSA-inhibitor complexes are removed from the circulation by different clearance mechanisms. The sites of metabolism of the different forms of PSA are different but include liver and kidney as main organs for uptake. There are indications that alpha2-M-R/LRP is involved in PSA elimination. Thus, factors which modulate the receptor function and expression as well as the concentration of its natural ligands may interfere with the steady state concentrations of different PSA forms in blood.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10458404     DOI: 10.1097/00005392-199909010-00086

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  6 in total

Review 1.  Tumor markers in prostate cancer I: blood-based markers.

Authors:  Shahrokh F Shariat; Axel Semjonow; Hans Lilja; Caroline Savage; Andrew J Vickers; Anders Bjartell
Journal:  Acta Oncol       Date:  2011-06       Impact factor: 4.089

2.  Assessment of intra-individual variation in prostate-specific antigen levels in a biennial randomized prostate cancer screening program in Sweden.

Authors:  Laila Bruun; Charlotte Becker; Jonas Hugosson; Hans Lilja; Anders Christensson
Journal:  Prostate       Date:  2005-11-01       Impact factor: 4.104

Review 3.  Screening for prostate cancer: an update.

Authors:  Shahrokh F Shariat; Peter T Scardino; Hans Lilja
Journal:  Can J Urol       Date:  2008-12       Impact factor: 1.344

4.  Copper is taken up efficiently from albumin and alpha2-macroglobulin by cultured human cells by more than one mechanism.

Authors:  Mizue Moriya; Yi-Hsuan Ho; Anne Grana; Linh Nguyen; Arrissa Alvarez; Rita Jamil; M Leigh Ackland; Agnes Michalczyk; Pia Hamer; Danny Ramos; Stephen Kim; Julian F B Mercer; Maria C Linder
Journal:  Am J Physiol Cell Physiol       Date:  2008-06-25       Impact factor: 4.249

5.  The relation of serum parathyroid hormone and serum calcium to serum levels of prostate-specific antigen: a population-based study.

Authors:  Halcyon G Skinner; Gary G Schwartz
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-10-27       Impact factor: 4.254

6.  Increase in percent free prostate-specific antigen in men with chronic kidney disease.

Authors:  Laila Bruun; Caroline Savage; Angel M Cronin; Jonas Hugosson; Hans Lilja; Anders Christensson
Journal:  Nephrol Dial Transplant       Date:  2008-11-21       Impact factor: 5.992

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.